IRWD Share Price

Open 15.55 Change Price %
High 15.87 1 Day 0.32 2.06
Low 15.46 1 Week -0.01 -0.06
Close 15.84 1 Month 0.92 6.17
Volume 876853 1 Year 0.12 0.76
52 Week High 19.94
52 Week Low 12.48
IRWD Important Levels
Resistance 2 16.22
Resistance 1 16.06
Pivot 15.72
Support 1 15.62
Support 2 15.46
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 3
As on 22nd Sep 2017 IRWD Share Price closed @ 15.84 and we RECOMMEND Sell for LONG-TERM with Stoploss of 16.38 & Sell for SHORT-TERM with Stoploss of 16.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for September
1st Target up-side 17.99
2nd Target up-side 19.42
3rd Target up-side 20.85
1st Target down-side 13.91
2nd Target down-side 12.48
3rd Target down-side 11.05
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.